Filing Details
- Accession Number:
- 0001127602-13-017189
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-05-16 17:38:59
- Reporting Period:
- 2013-05-14
- Filing Date:
- 2013-05-16
- Accepted Time:
- 2013-05-16 17:38:59
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 318154 | Amgen Inc | AMGN | Biological Products, (No Disgnostic Substances) (2836) | 953540776 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1032669 | Frank Biondi | One Amgen Center Drive Thousand Oaks CA 91320-1799 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2013-05-14 | 5,000 | $62.55 | 34,780 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2013-05-14 | 5,000 | $50.44 | 39,780 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2013-05-14 | 10,000 | $108.43 | 29,780 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Nqso (Right to Buy) | Disposition | 2013-05-14 | 5,000 | $0.00 | 5,000 | $62.55 |
| Common Stock | Nqso (Right to Buy) | Disposition | 2013-05-14 | 5,000 | $0.00 | 5,000 | $50.44 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2007-04-26 | 2014-04-26 | No | 4 | M | Direct |
| 0 | 2009-04-28 | 2016-04-28 | No | 4 | M | Direct |
Footnotes
- The price reported is an average price. The prices ranged from $108.25 to $108.64 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
- These shares include 352 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.
Billionaire Hedge Funds
